** Shares of cancer drugmaker Verastem VSTM.O rise 3% to $6.89 in afternoon trading
** VSTM says the U.S. FDA approved its combo therapy to treat patients with a rare type of ovarian cancer
** The therapy, under the brand name Avmapki Fakzynja Co-pack, is for adults with low-grade serous ovarian cancer who have received prior treatment and have a mutated KRAS gene
** Jefferies analyst Kelly Shi said the therapy has shown better results than traditional chemotherapy and a commonly used treatment, Novartis' NOVN.S trametinib, sparking "strong adoption enthusiasm" among doctors
** Therapy will be available in one week - VSTM
** As of last close, stock up 29% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.